Active substances
Amlodipine + Irbesartan
- SFDA 11
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| APROVASC 150MG/10MG F.C.TABLET | 150,10 mg,mg | Tablet · Oral use | 28 Blister | SAR 95.65 | NCE · Prescription | sanofi-aventis de Mexico, S.A. de C.V. | Valid |
| APROVASC 150MG/5MG F.C.TABLET | 150,5 mg,mg | Tablet · Oral use | 28 Blister | SAR 95.65 | NCE · Prescription | sanofi-aventis de Mexico, S.A. de C.V. | Valid |
| APROVASC 300MG/10MG F.C.TABLET | 300,10 mg,mg | Tablet · Oral use | 28 Blister | SAR 135.95 | NCE · Prescription | sanofi-aventis de Mexico, S.A. de C.V. | Valid |
| APROVASC 300MG/5MG F.C.TABLET | 300,5 mg,mg | Tablet · Oral use | 28 Blister | SAR 135.95 | NCE · Prescription | sanofi-aventis de Mexico, S.A. de C.V. | Valid |
| Gizamlo | 300,10 mg,mg | Film-coated tablet · Oral use | 30 Blister | SAR 61.10 | Generic · Prescription | DAR ALDAWA | Valid |
| Gizamlo | 300,5 mg,mg | Film-coated tablet · Oral use | 30 Blister | SAR 61.10 | Generic · Prescription | DAR ALDAWA | Valid |
| Gizamlo | 150,5 mg,mg | Film-coated tablet · Oral use | 30 Blister | SAR 61.10 | Generic · Prescription | DAR ALDAWA | Valid |
| REDUVASC 150MG/10MG F.C.TABLET | 150,10 mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 81.30 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| REDUVASC 150MG/5MG F.C.TABLET | 150,5 mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 81.30 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| REDUVASC 300MG/10MG F.C.TABLET | 300,10 mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 115.55 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| REDUVASC 300MG/5MG F.C.TABLET | 300,5 mg,mg | Film-coated tablet · Oral use | 28 Blister | SAR 115.55 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
Indications — CHI Daman Drug Formulary
HYPERTENSION
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.